[English]  [Pусский]  [中文]  
 
ctt-journal > Voropaeva et al. (Abstract)

Voropaeva et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract01
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment

Survival of patients with non-Hodgkin's lymphomas and changes in Arg72Pro gene p53

Еlena N. Voropaeva, Тatiana I. Pospelova, Мichail I. Voevoda, Оlga V. Beresina

GOU VPO Novosibirsk state medical university, Scientific Research Institute of Therapy of the Russian academy of medical sciences SB, Novosibirsk, Russia

Correspondence: Еlena Nikolaevna Voropaeva, GOU VPO Novosibirsk state medical university, 52, Krasnij prospect, Novosibirsk, 630017, Russia; E-mail: vena.81@spam is badmail.ru

Abstract  

The polymorphism Arg72Pro gene p53 is characterized by a change of cytosine on glycine in the 72-codon of ex4, that leads to two different variants of protein p53: with either aminoacid arginine or proline in the area, involved in apoptotic activity p53. It is shown that the 72Arg-form p53 initialized cellular death more effectively, than the 72Pro-form. However, the 72Pro-variant more effectively provides for DNA reparation.

Purpose: To analyze the 3-year survival of patients with non-Hodgkin’s lymphomas (NHL) depending on changes in the polymorphic locus Arg72Pro gene p53.

Methods: 99 patients with NHL were examined, 42 of them with aggressive and 57 with indolent lymphomas. The polymorphism gene p53 was researched by PCR-PLRF-analysis. The Kaplan-Meier method was used for survival analysis.

Results: In the examined group the 3-year overall survival was 76%. Reduction of survival was noted in patients with aggressive lymphomas having Pro-variant gene p53, in comparison with persons with normal genotype Arg/Arg: 83% against 95%. The patients with indolent lymphomas and Pro-variant of the gene p53 had a more successful 3-year survival (79%) in comparison with Arg/Arg persons (48%) (p<0.05).

Conclusions: The results of this study indicate that changes in 72-codon of ex4 gene p53 may be potential markers of prognosis of a NHL patient’s survival. Future studies to determine the mechanism of their influence upon survival of the patients with different variants of NHL are required.

Keywords: non-Hodgkin’s lymphomas, survival, polymorphism, gene р53

 

<-- Previous abstract        Contents        Next abstract -->

Contribute a comment

Top